The LLR TAP IcICLLe Trial: detailed assessment of the response to ibrutinib provides insights into the mode of action and pattern of response in treatment nayve and refractory CLL.
Authors
Rawstron, AMunir, T
Eccleston, K
Dalal, S
de Tute, R
Brock, K
Yates, F
Bloor, Adrian
Fox, C
Fegan, C
Macdonald, D
Hillmen, P
Affiliation
St James' Institute of Oncology, LeedsIssue Date
2015